Does intravenous (IV) nitroglycerin reduce contrast-induced nephropathy (CIN)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Intravenous nitroglycerin is not recommended for the prevention of contrast-induced nephropathy (CIN) due to lack of consistent evidence supporting its effectiveness. The 2014 ESC/EACTS guidelines on myocardial revascularization do not mention IV nitroglycerin as a recommended strategy for preventing CIN 1. Instead, the guidelines emphasize the importance of hydration with isotonic saline, use of low-osmolar or iso-osmolar contrast media, and minimizing contrast volume as key measures to prevent CIN. Some key recommendations include:

  • Hydration with isotonic saline is recommended for patients with moderate-to-severe chronic kidney disease (CKD) 1
  • Use of low-osmolar or iso-osmolar contrast media is recommended, with a suggested volume of less than 350 mL or less than 4 mL/kg, or a total contrast volume/GFR of less than 3.4 1
  • Short-term, high-dose statin therapy should be considered for patients undergoing coronary angiography or MDCT 1 The primary pathophysiological mechanisms underlying CIN involve direct tubular toxicity and renal vasoconstriction, which IV nitroglycerin does not adequately address. While nitroglycerin is a vasodilator that theoretically could improve renal blood flow, clinical studies have yielded mixed results, with most showing no significant protective effect against CIN. Therefore, the routine use of IV nitroglycerin for preventing CIN is not supported by current evidence.

From the Research

Contrast-Induced Nephropathy Prevention

The provided studies do not specifically investigate the effect of intravenous (IV) nitroglycerin on contrast-induced nephropathy (CIN). However, they discuss various strategies for preventing CIN, including:

  • Intravenous hydration with isotonic saline or sodium bicarbonate 2, 3, 4
  • Use of N-acetylcysteine 2, 3
  • Minimizing contrast media volume 3, 5
  • Withdrawal of non-steroidal anti-inflammatory drugs 3
  • Use of iso-osmolar or low-osmolar contrast media 3

Key Findings

Some key findings from the studies include:

  • Intravenous hydration is effective in reducing the incidence of CIN in high-risk patients 6, 2, 4
  • The addition of N-acetylcysteine or sodium bicarbonate to intravenous hydration may not have a significant effect on the incidence of CIN 2
  • Minimizing contrast media volume and using iso-osmolar or low-osmolar contrast media may help reduce the risk of CIN 3, 5

Limitations

The studies provided do not investigate the specific effect of IV nitroglycerin on CIN. Therefore, there is no evidence to support or refute the use of IV nitroglycerin for preventing CIN 6, 2, 3, 5, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Prevention of contrast-induced nephropathy: A randomized controlled trial of sodium bicarbonate and N-acetylcysteine.

The International journal of angiology : official publication of the International College of Angiology, Inc, 2009

Research

[Contrast induced nephropathy].

Wiener klinische Wochenschrift, 2009

Research

Contrast nephropathy : an evidence-based approach to prevention.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.